bioAffinity Technologies

Update in progress

BIAF (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

bioAffinity Technologies, Inc. develops non-invasive diagnostic tests to detect early-stage lung cancer and other lung diseases using flow cytometry and automated analysis in the United States. It has two segments: Diagnostic Research and Development and Laboratory Services. Its CyPath Lung test analyzes sputum to identify cancer- and cancer-related cells shed from a tumor. The company collaborates with Brooke Army Medical Center on inflammatory biomarkers for asthma and COPD. Founded 2014, based in San Antonio, Texas.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive